



COPY OF PAPERS  
ORIGINALLY FILED

PATENT CASE IN01159K1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re Application of:

A. Saksena *et al.*

Serial No.: 10/052,386

Filed: January 18, 2002

)  
) Examiner: Not assigned yet  
)  
) Group Art Unit: Not assigned yet  
)  
)  
) Atty. Docket No.: IN01159K1

For: **NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF  
HEPATITIS C VIRUS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

Documents cited in the Application:

U.S. 5,712,145  
WO 89/04669  
WO 98/17679  
WO 98/22496  
WO 99/07734  
WO 00/09558  
WO 00/09543  
EP 381 216

Publications:

Pizzi *et al.* (1994) *Proc. Natl. Acad. Sci (USA)* 91:888-892  
Failla *et al.* (1996) *Folding & Design* 1:35-42  
Kollykhalov *et al.* (1994) *J. Virol.* 68:7525-7533  
Komoda *et al.* (1994) *J. Virol.* 68:7351-7357  
Landro *et al.* (1997) *Biochem.* 36:9340-9348  
Ingallinella *et al.* (1998) *Biochem.* 37:8906-8914  
Llinàs-Brunet *et al.* (1998) *Bioorg. Med. Chem. Lett.* 8:1713-1718  
Martin *et al.* (1998) *Biochem.* 37:11459-11468  
Dimasi *et al.* (1997) *J. Virol.* 71:7461-7469  
Martin *et al.* (1997) *Protein Eng.* 10:607-614  
Elzouki *et al.* (1997) *J. Hepat.* 27:42-48  
*BioWorld Today* 9(217): 4 (November 10, 1998)  
Berenguer *et al.* (1998) *Proc. Assoc. Am. Physicians* 110(2):98-112  
Hoofnagle *et al.* (1997) *N. Engl. J. Med.* 336:347  
R. Zhang *et al.*, *Analytical Biochemistry*, 270 (1999) 268-275

D. L. Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401  
K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520  
K. Holmberg *et al*, *Acta Chem. Scand.*, B33 (1979) 410-412  
A. Marchetti *et al*, *Synlett.*, S1 (1999) 1000-1002  
W. Han *et al*, *Bioorganic & Biomedical Chem Lett.*, 10 (2000) 711-713  
S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine  
Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4,  
Part 2, October 1999), *Abstract No. 615* (Proceedings of AASLD 50<sup>th</sup> Annual Meeting,  
Dallas, Texas, November 5-9, 1999.  
L. Hughes, *Org. Reactions*, 42 (1992) 335.  
R. F. Heck, *Org. Reactions*, 27 (1989) 345-390.

All the above-noted documents, along with copies of the references, were submitted in the  
IDS and PTO-1449 that Applicant filed for the priority case, IN01159K, Serial No.  
09/908,955, filed July 19, 2001. Applicants are, therefore, not sending copies of the  
documents again. If, however, the Examiner needs copy of any of the references, the  
Examiner is invited to contact the undersigned.

The submission of these documents is not to be presumed as an admission that these  
documents are prior art. Since no Office Action has issued on the merits of this case,  
Applicants believe that no fee is due at this time. If, however, any fees are due, the Office  
may charge such fees to Deposit Account No. 19-0365.

July 30, 2002  
Schering-Plough Corporation  
2000 Galloping Hill Road  
Patent Department, K-6-1,1990  
Kenilworth, NJ 07033  
Tel: (908) 298-5068  
Fax: (908) 298-5388

Respectfully submitted,



Palaiyur S. Kalyanaraman  
Attorney for Applicants  
Reg. No. 34,634

I hereby certify that this correspondence  
is being deposited with the U.S. Postal  
Service as First Class Mail in an envelope  
addressed to Assistant Commissioner for  
Patents, Washington, D.C. 20231 on


July 30, 2002

Palaiyur S. Kalyanaraman  
Registered Representative

  
Signature and Date of Signature

03co

COPY OF PAPERS  
ORIGINALLY FILED



Please type a plus sign (+) inside this box → ☐

Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	10.052.386	
	<b>Filing Date</b>	January 18, 2002	
	<b>First Named Inventor</b>	SAKSENA, et al	
	<b>Group Art Unit</b>	TBA	
	<b>Examiner Name</b>	TBA	
<b>Total Number of Pages in This Submission</b>	5	<b>Attorney Docket Number</b>	IN01159K1

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Charge of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below)  Return Post Card Form 1449
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	SCHERING-PLOUGH CORPORATION PATENT DEPARTMENT, K-6-1-1990 PALAIYUR S. KALYANARAMAN REG. NO. 34, 634
Signature	
Date	July 30, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: July 30, 2002			
Typed or printed name	PALAIYUR S. KALYANARAMAN		
Signature		Date	July 30, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

AUG 06 2002

COPY OF PAPERS  
ORIGINALLY FILED

Sheet 1 of 1

FORM PTO 449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
IN01159K1SERIAL NO.:  
10/052,386INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
SAKSENA, et alFILING DATE:  
01/18/2002GROUP:  
TBA

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AD	WO 01 74768	10/11/01	WIPO			
AE	WO 01 40262	06/07/01	WIPO			
AF	WO 00 52032	09/08/00	WIPO			
AG	WO 99 07734	02/18/99	WIPO			
AH	WO 98 17679	04/30/98	WIPO			
AI						
AJ						
AK						
AJ						
AK						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	WEI HAN, et al, "alpha-Ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors", <i>BIOORGANIC &amp; MEDICINAL CHEMISTRY LETTERS</i> , Vol. 10, No. 8, (2000), pp. 711-713.
AM	LLINAS-BRUNET MONTSE, et al, "Studies on the c-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease", <i>BIOORGANIC &amp; MEDICINAL CHEMISTRY LETTERS</i> , Vol. 8, No. 19, (1998), pp. 2719-2724.
AN	
AO	
AP	
AQ	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.